Neuroendocrine evidence of normal hypothalamus-pituitary dopaminergic function in Huntington's disease

Neuroendocrinology Letters

Volumn 31, Issue 3, 2010, Pages 359-362

  Markianos, Manolis ^a   Panas, Marios ^a   Kalfakis, Nikos ^a   Hatzimanolis, John ^a   Vassilopoulos, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CAG repeat number; Haloperidol challenge test; Huntington's disease; Prolactin

Indexed keywords

HALOPERIDOL; PROLACTIN; DOPAMINE; HTT PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN;

ADULT; AGED; ARTICLE; CAG REPEAT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; PSYCHOSIS; SEX DIFFERENCE; BLOOD; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT; TRINUCLEOTIDE REPEAT;

ADULT; DOPAMINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HALOPERIDOL; HUMANS; HUNTINGTON DISEASE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROLACTIN; SEX CHARACTERISTICS; TRINUCLEOTIDE REPEATS;

EID: 77955461946     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Augood SJ, Faull RL, Emson PC (1997). Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol. 42: 215-221. (Pubitemid 27340467)
2. Caron MG, Beaulieu M, Raymond V, Cagne B, Drouin J, Lefkowitz RJ, Labrie F (1978). Dopaminergic receptors in the anterior pituitary gland. J Biol Chem. 253: 2244-2253.
3. Cha JH, Kosinski CM, Kerner JA, Alsdord SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA. 95: 6480-6485.
4. Durso R, Tamminga CA, Ruggeri S, Denaro A, Kuo S, Chase TN (1983). Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease. J Neurol Neurosurg Psychiatry. 46: 1134-1137. (Pubitemid 14212829)
5. Ferrante RJ, Kowall NW, Beal MF, Richardson EP, Bird ED, Martin JB (1985). Selective sparing of a class of striatal neurons in Huntington's disease. Science. 230: 561-563.
6. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000). Prolactin: Structure, function, and regulation of secretion. Pharmacol Rev. 80: 1523-1631.
7. Gruen PH, Sachar EJ, Langer G, Altman N, Leiter M, Frantz A, Halpern MA (1978). Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 35: 108-116. (Pubitemid 8263443)
8. Hayden MR, Vinik AL, Paul M, Beighton P (1977). Impaired prolactin release in Huntington's chorea. Evidence for dopaminergic excess. Lancet. 2(8035): 423-426.
9. Huntington Study Group (1996). Unified Huntington's Disease Rating Scale. Reliability and consistency. Mov Disord. 11: 136-142.
10. Kassubek J, Gaus W, Landwehrmeyer GB (2004). Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 62: 523-524. (Pubitemid 38200883)
11. Kremer HP, Roos RA, Dingjan GM, Marani E, Bots GT (1990). Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol. 49: 371-382. (Pubitemid 20207798)
12. Lavin PJ, Bone I, Sheridan P (1981 ). Studies of hypothalamic function in Huntington's chorea. J Neurol Neurosurg Psychiatry. 44: 414-418. (Pubitemid 11046277)
13. Leong DA, Frawlley LS, Neill JD (1983). Neuroendocrine control of prolactin secretion. Annu Rev Physiol. 45: 109-127.
14. Markianos M, Hatzimanolis J, Lykouras L (2001). Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 251: 141-146.
15. Murri L, Iudice A, Muratorio A, Polleri A, Barreca T, Murialdo G (1980). Spontaneous nocturnal plasma prolactin ad growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. Eur Neurol. 19: 198-206. (Pubitemid 10150599)
16. Petersen A, Gil J, Maat-Schieman ML, Bjorkvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlen P, Li JY, Roos RA, Sundler F, Mulder H, Btundin P (2005). Orexin loss in Huntington's disease. Hum Mol Genet. 14: 39-47.
17. Petersen A, Bjorkvist M (2006). Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neuroscience. 24: 961-967.
18. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB (1988). Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 85: 5733-5737.
19. Shoulson I, Fahn S (1979). Huntington's disease. Clinical care and evaluation. Neurology. 29: 1-3.
20. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL (1993). Widespread expression of the human and rat Huntington's disease gene in brain and non-neural tissues. Nat Genet. 5: 259-265.
21. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985). Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 44: 559-577.
22. Warner JP, Barron LH, Brock DJH (1993). A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes. 7: 235-239.
23. Weeks RA, Piccini P, Harding AE, Brooks DJ (1996). Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington' disease. Ann Neurol. 40: 49-54. (Pubitemid 26250142)
24. Zucker B, Luthi-Carter R, Kama JA, Dunah AW, Stern EA, Fox JH, Standaert DG, Young AB, Augood SJ (2005). Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Molec Genetics. 14: 179-189.